Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | PLAU | P00749 | 5/20 | 0.64 |
| ▸ | ERN1 | O75460 | 2/20 | 0.58 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.56 |
| ▸ | PLAT | P00750 | 2/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27715902 | 0.89 | CA12 (0.71) | CA12CA9CA1CA2PLAU | |
| SCHEMBL29441704 | 0.88 | CA12 (0.61) | CA12CA9CA1CA2PLAU | |
| SCHEMBL2875365 | 0.88 | CA12 (0.61) | CA12CA9CA1CA2PLAU | |
| SCHEMBL68931 | 0.88 | CA12 (0.69) | CA12CA9CA1CA2PLAU | |
| SCHEMBL67941 | 0.88 | CA12 (0.68) | CA12CA9CA1CA2PLAU | |
| Hydrochloric Acid SCHEMBL6233341 | 0.87 | CA12 (0.60) | CA12CA9CA1CA2PLAU | |
| SCHEMBL29410906 | 0.86 | TSHR (0.67) | CA12CA9CA1CA2PLAU | |
| SCHEMBL1221576 | 0.86 | TSHR (0.67) | CA12CA9CA1CA2PLAU | |
| SCHEMBL27614229 | 0.85 | PLAU (0.54) | CA12CA9CA1CA2PLAU | |
| SCHEMBL30443216 | 0.85 | CA12 (0.66) | CA12CA9CA1CA2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665373-A2 | SELECT THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS Oncology, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4559908-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | S2CBio Inc. (KR) | 2025-05-28 | — | — | EP | disclosed |
| US-20250144078-A1 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | SYMERES NETHERLANDS B.V. (NL) | 2025-05-08 | — | — | US | disclosed |
| US-20250034112-A1 | IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | UNIV YALE (US) | 2025-01-30 | — | — | US | disclosed |
| CN-119301105-A | Thiostrepton-based compounds for the treatment of cancer and preparation thereof | RS肿瘤学有限责任公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2025-01-09 | — | — | US | disclosed |
| EP-4479390-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS Oncology, LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024173644-A2 | SELECT THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024019541-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-25 | — | — | WO | disclosed |
| US-20110160192-A1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| WO-2011050323-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2011-04-28 | — | — | WO | disclosed |
| EP-1727808-B1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| EP-1727808-B1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| EP-1727808-A2 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | Spirogen Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005085177-A2 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| CN-1300279-A | Modulators of protein tyrosine phosphatases | NOVO NORDISK AS (DK) | 2001-06-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034112-A1 | IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | JAK2, JAK1, MCL1 | CA12 4763/4885CA9 4851/4885CA1 4789/4885 |
| US-20110160192-A1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | PCNA, POLL, XPA | CA12 4401/4885CA9 3933/4885CA1 4609/4885 |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | PCNA, POLL, DNA2 | CA12 4402/4885CA9 3928/4885CA1 4575/4885 |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | CA12 1740/4885CA9 465/4885CA1 1078/4885 |
| US-20250144078-A1 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | TYMS, TOP1, TOP2A | CA12 2574/4885CA9 339/4885CA1 3620/4885 |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | CA12 1739/4885CA9 474/4885CA1 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.